Published in Cancer Immunol Immunother on April 17, 2008
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2012) 2.37
Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov (2012) 2.29
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res (2012) 1.84
Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. J Immunol (2009) 1.77
Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One (2011) 1.73
IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype. PLoS One (2014) 1.40
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother (2014) 1.39
Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J (2010) 1.36
The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One (2011) 1.32
Imaging correlates of differential expression of indoleamine 2,3-dioxygenase in human brain tumors. Mol Imaging Biol (2009) 1.30
Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol (2010) 1.29
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol (2010) 1.22
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res (2009) 1.13
Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One (2011) 1.11
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy (2009) 1.10
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res (2015) 1.09
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01
Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest (2012) 1.00
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Front Immunol (2013) 0.99
Tryptophan-catabolizing enzymes - party of three. Front Immunol (2014) 0.99
Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J Neuroinflammation (2013) 0.98
Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis. J Histochem Cytochem (2012) 0.95
The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol (2011) 0.94
The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. Clin Exp Immunol (2011) 0.92
Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7. J Invest Dermatol (2013) 0.92
IDO2 in Immunomodulation and Autoimmune Disease. Front Immunol (2014) 0.92
Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. Br J Cancer (2015) 0.90
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol (2014) 0.89
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol (2012) 0.89
Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS One (2011) 0.89
The role of placental tryptophan catabolism. Front Immunol (2014) 0.88
The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol (2013) 0.86
IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease. Int J Tryptophan Res (2010) 0.86
Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases. Front Immunol (2012) 0.85
Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer (2015) 0.84
Retracted Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev (2015) 0.84
Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol (2015) 0.84
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity. Vaccines (Basel) (2015) 0.83
Can tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol (2012) 0.83
Metabolomics for biomarker discovery in gastroenterological cancer. Metabolites (2014) 0.81
Molecular evolution and characterization of fungal indoleamine 2,3-dioxygenases. J Mol Evol (2010) 0.81
Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model. Immunology (2015) 0.81
Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer. Transl Res (2015) 0.80
Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas. Virchows Arch (2009) 0.80
Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors. Brain Tumor Res Treat (2013) 0.80
Activation of indoleamine 2,3-dioxygenase in patients with scrub typhus and its role in growth restriction of Orientia tsutsugamushi. PLoS Negl Trop Dis (2012) 0.79
Influence of tryptophan contained in 1-Methyl-Tryptophan on antimicrobial and immunoregulatory functions of indoleamine 2,3-dioxygenase. PLoS One (2012) 0.79
Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2. Exp Mol Med (2014) 0.79
Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients. Clin Exp Immunol (2015) 0.79
Development of 1-N-(11)C-Methyl-l- and -d-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan. Sci Rep (2015) 0.78
Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. Cancer Lett (2016) 0.78
Interferon Lambda Upregulates IDO1 Expression in Respiratory Epithelial Cells After Influenza Virus Infection. J Interferon Cytokine Res (2015) 0.78
Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment. Front Immunol (2017) 0.77
Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice. Cancer Sci (2015) 0.77
Pharmacokinetics of 1-methyl-L-tryptophan after single and repeated subcutaneous application in a porcine model. Exp Anim (2015) 0.77
Novel drugs that target the metabolic reprogramming in renal cell cancer. Cancer Metab (2016) 0.76
IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma. Oncotarget (2016) 0.76
Indoleamine 2,3-dioxygenase expression in patients with allergic rhinitis: a case-control study. Clin Transl Allergy (2011) 0.76
Effects of various phytochemicals on indoleamine 2,3-dioxygenase 1 activity: galanal is a novel, competitive inhibitor of the enzyme. PLoS One (2014) 0.76
Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth. Oncotarget (2016) 0.75
Serum Immune System Biomarkers Neopterin and Interleukin-10 Are Strongly Related to Tryptophan Metabolism in Healthy Young Adults. J Nutr (2016) 0.75
Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. Cell Mol Life Sci (2017) 0.75
Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma. World J Gastroenterol (2017) 0.75
Tryptophan Metabolism in Patients With Chronic Kidney Disease Secondary to Type 2 Diabetes: Relationship to Inflammatory Markers. Int J Tryptophan Res (2017) 0.75
IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity. Clin Med Insights Pathol (2016) 0.75
High-Fat Diet and Voluntary Chronic Aerobic Exercise Recover Altered Levels of Aging-Related Tryptophan Metabolites along the Kynurenine Pathway. Exp Neurobiol (2017) 0.75
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain Behav Immun (2017) 0.75
Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg (2012) 19.78
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol (2009) 4.38
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med (2002) 3.75
Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A (2005) 3.75
Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation (2008) 3.43
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88
A new endoscopic over-the-scope clip system for treatment of lesions and bleeding in the GI tract: first clinical experiences. Gastrointest Endosc (2007) 2.72
Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol (2002) 2.72
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood (2003) 2.50
The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem (2002) 2.39
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes (2009) 2.36
C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med (2009) 2.29
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res (2006) 2.26
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol (2004) 2.22
Critical evaluation of the amino acid triplet-epitope matching concept in cadaver kidney transplantation. Transplantation (2004) 2.13
Functional importance of laparoscopic sleeve gastrectomy for the lower esophageal sphincter in patients with morbid obesity. Obes Surg (2012) 2.11
Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios. Clin Chem (2009) 2.02
The Over-The-Scope Clip (OTSC) for the treatment of gastrointestinal bleeding, perforations, and fistulas. Surg Endosc (2011) 1.98
Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques (2003) 1.95
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92
H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet (2008) 1.85
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol (2005) 1.85
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A (2002) 1.85
Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood (2004) 1.83
CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood (2009) 1.79
Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr (2008) 1.78
A new wound-based severity score for diabetic foot ulcers: A prospective analysis of 1,000 patients. Diabetes Care (2006) 1.78
Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant (2003) 1.76
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
Neurological symptoms in patients with biopsy proven celiac disease. Mov Disord (2009) 1.69
Characterizing the N-terminal processing motif of MHC class I ligands. J Immunol (2008) 1.68
No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation (2011) 1.67
Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun (2009) 1.65
Tumor-associated MICA is shed by ADAM proteases. Cancer Res (2008) 1.64
Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience. Oncologist (2007) 1.63
Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J Immunol (2004) 1.63
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun (2010) 1.62
MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res (2003) 1.60
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol (2011) 1.56
Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs. Crit Care Med (2003) 1.55
Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation (2008) 1.55
Vasopressin, but not fluid resuscitation, enhances survival in a liver trauma model with uncontrolled and otherwise lethal hemorrhagic shock in pigs. Anesthesiology (2003) 1.53
Primary blood neutrophils express a functional cell surface Toll-like receptor 9. Eur J Immunol (2013) 1.52
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
Malignancy in renal transplantation. J Am Soc Nephrol (2004) 1.50
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2007) 1.48
Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int (2012) 1.47
Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation (2009) 1.47
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol (2003) 1.46
Simultaneous adrenal and extra-adrenal myelolipoma - an uncommon incident: case report and review of the literature. World J Surg Oncol (2008) 1.46
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. 1991. J Immunol (2006) 1.45
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother (2009) 1.44
Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int (2005) 1.43
Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics. Cancer Invest (2012) 1.42
Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol (2012) 1.42
Efficacy of topical pale sulfonated shale oil in the treatment of venous leg ulcers: a randomized, controlled, multicenter study. J Vasc Surg (2006) 1.42
The impact of a micro-lightguide spectrophotometer on the intraoperative assessment of hepatic microcirculation: a pilot study. Microvasc Res (2009) 1.41
Ex vivo perfusion with mitomycin C containing solution prolongs heart graft survival in rats. Transplantation (2006) 1.41
Markers of Bone Metabolism in Obese Individuals Undergoing Laparoscopic Sleeve Gastrectomy. Obes Surg (2015) 1.41
Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2006) 1.40
Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother (2008) 1.40
Adenocarcinoma arising in a cystic duplication of the small bowel: case report and review of literature. World J Surg Oncol (2012) 1.38
Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation (2013) 1.36
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
ALPPS in right trisectionectomy: a safe procedure to avoid postoperative liver failure? J Gastrointest Surg (2013) 1.32
MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics (2003) 1.31
Anorectal malignant melanoma: extensive 45-year review and proposal for a novel staging classification. J Am Coll Surg (2013) 1.29
Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res (2002) 1.28
A cell line model for the differentiation of human dendritic cells. Biochem Biophys Res Commun (2005) 1.28
Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem (2006) 1.26
Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics (2006) 1.26
Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood (2004) 1.26
Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab (2011) 1.24
Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood (2012) 1.23
Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res (2002) 1.23
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol (2008) 1.20
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20
Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem (2008) 1.20
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
Complete hepatic ischemia due to torsion of a large accessory liver lobe: first case to require transplantation. Transpl Int (2005) 1.19
Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons. Nat Commun (2013) 1.18
Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J Biol Chem (2013) 1.18
Evaluation of mitochondrial respiratory function in small biopsies of liver. Anal Biochem (2002) 1.17
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol (2006) 1.14
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology (2008) 1.14
Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol (2004) 1.13